Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71

Vaccine

Volumn 33, Issue 39, 2015, Pages 5087-5094

  Zhang, Chao ^a   Yang, Yong ^a   Chi, Yudan ^a   Yin, Jieyun ^a   Yan, Lijun ^a   Ku, Zhiqiang ^a   Liu, Qingwei ^a   Huang, Zhong ^a   Zhou, Dongming ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

Adenovirus; Bivalent vaccine; Coxsackievirus A16; Enterovirus 71; Hexon

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; NEUTRALIZING ANTIBODY; VIRUS VACCINE; MEMBRANE ANTIGEN; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ADENOVIRIDAE; ANIMAL CELL; ANTIGEN BINDING; ARTICLE; CLONING; CONTROLLED STUDY; COXSACKIEVIRUS A16; ENTEROVIRUS 71; FEMALE; HAND FOOT AND MOUTH DISEASE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SUCKLING ANIMAL; SURVIVAL RATE; VACCINATION; VIRION; VIRUS PARTICLE; ANIMAL; ASIA; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; ENTEROVIRUS; ENTEROVIRUS A; GENE VECTOR; GENETICS; HAND, FOOT AND MOUTH DISEASE; HUMAN; IMMUNOLOGY; SURVIVAL ANALYSIS;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, SURFACE; ASIA; DISEASE MODELS, ANIMAL; ENTEROVIRUS; ENTEROVIRUS A, HUMAN; EPITOPES; FEMALE; GENETIC VECTORS; HAND, FOOT AND MOUTH DISEASE; HUMANS; MICE, INBRED BALB C; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84941730516     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.016     Document Type: Article

References (44)

1. Liu Y., Wang X., Sun D., Ding S., Zhang B., Du Z., et al. Detecting spatial-temporal clusters of HFMD from 2007 to 2011 in Shandong Province, China. PLOS ONE 2013, 8:e63447.
2. Tan X., Huang X., Zhu S., Chen H., Yu Q., Wang H., et al. The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS ONE 2011, 6:e25662.
3. Mao L.X., Wu B., Bao W.X., Han F.A., Xu L., Ge Q.J., et al. Epidemiology of hand, foot, and mouth disease and genotype characterization of Enterovirus 71 in Jiangsu, China. J Clin Virol 2010, 49:100-104.
4. Wang Y.R., Sun L.L., Xiao W.L., Chen L.Y., Wang X.F., Pan D.M. Epidemiology and clinical characteristics of hand foot, and mouth disease in a Shenzhen sentinel hospital from 2009 to 2011. BMC Infect Dis 2013, 13:539.
5. Li W., Yi L., Su J., Lu J., Ke C., Zeng H., et al. Seroprevalence of human enterovirus 71 and coxsackievirus A16 in Guangdong, China, in pre- and post-2010 HFMD epidemic period. PLOS ONE 2013, 8:e80515.
6. Zhang Y., Tan X.J., Wang H.Y., Yan D.M., Zhu S.L., Wang D.Y., et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 2009, 44:262-267.
7. Zhu Q., Hao Y., Ma J., Yu S., Wang Y. Surveillance of hand, foot, and mouth disease in mainland China (2008-2009). Biomed Environ Sci 2011, 24:349-356.
8. Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013, 381:2024-2032.
9. Lee M.S., Tseng F.C., Wang J.R., Chi C.Y., Chong P., Su I.J. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 2012, 6:e1737.
10. Ku Z., Liu Q., Ye X., Cai Y., Wang X., Shi J., et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 2014, 32:4296-4303.
11. Cai Y., Ku Z., Liu Q., Leng Q., Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 2014, 32:2406-2412.
12. Tian X., Su X., Li X., Li H., Li T., Zhou Z., et al. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon. PLoS ONE 2012, 7:e41381.
13. Cai Y., Liu Q., Huang X., Li D., Ku Z., Zhang Y., et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013, 31:2215-2221.
14. Ye X., Ku Z., Liu Q., Wang X., Shi J., Zhang Y., et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 2014, 88:72-81.
15. Shi J., Huang X., Liu Q., Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine 2013, 31:2130-2136.
16. Sette A., Newman M., Livingston B., McKinney D., Sidney J., Ishioka G., et al. Optimizing vaccine design for cellular processing. MHC binding and TCR recognition. Tissue Antigens 2002, 59:443-451.
17. Sette A., Keogh E., Ishioka G., Sidney J., Tangri S., Livingston B., et al. Epitope identification and vaccine design for cancer immunotherapy. Curr Opin Investig Drugs 2002, 3:132-139.
18. Gori A., Longhi R., Peri C., Colombo G. Peptides for immunological purposes: design, strategies and applications. Amino Acids 2013, 45:257-268.
19. Crompton J., Toogood C.I., Wallis N., Hay R.T. Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 1994, 75(Pt 1):133-139.
20. Zhou D., Wu T.L., Emmer K.L., Kurupati R., Tuyishime S., Li Y., et al. Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus. Mol Ther 2013, 21:696-706.
21. Dudareva M., Andrews L., Gilbert S.C., Bejon P., Marsh K., Mwacharo J., et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009, 27:3501-3504.
22. Xiang Z., Li Y., Cun A., Yang W., Ellenberg S., Switzer W.M., et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 2006, 12:1596-1599.
23. Ersching J., Hernandez M.I., Cezarotto F.S., Ferreira J.D., Martins A.B., Switzer W.M., et al. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology 2010, 407:1-6.
24. Zhang F., Hao C., Zhang S., Li A., Zhang Q., Wu W., et al. Oral immunization with recombinant enterovirus 71 VP1 formulated with chitosan protects mice against lethal challenge. Virol J 2014, 11:80.
25. Chiu C.H., Chu C., He C.C., Lin T.Y. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 2006, 8:1671-1678.
26. Chen H.L., Huang J.Y., Chu T.W., Tsai T.C., Hung C.M., Lin C.C., et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008, 26:2882-2889.
27. Liu Q., Huang X., Ku Z., Wang T., Liu F., Cai Y., et al. Characterization of enterovirus 71 capsids using subunit protein-specific polyclonal antibodies. J Virol Methods 2013, 187:127-131.
28. Ku Z., Ye X., Huang X., Cai Y., Liu Q., Li Y., et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLOS ONE 2013, 8:e57601.
29. Zhang C., Ku Z., Liu Q., Wang X., Chen T., Ye X., et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine 2015, 33:2335-2341.
30. Liu Q., Yan K., Feng Y., Huang X., Ku Z., Cai Y., et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 2012, 30:6642-6648.
31. Liu Q., Ku Z., Cai Y., Sun B., Leng Q., Huang Z. Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins. J Virol Methods 2011, 173:115-120.
32. Wang X., Xing M., Zhang C., Yang Y., Chi Y., Tang X., et al. Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China. Emerg Microb Infect 2014, 3:e30.
33. Zhang Q., Su X., Seto D., Zheng B.J., Tian X., Sheng H., et al. Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine 2009, 27:1145-1153.
34. Zhang C., Zhu R., Yang Y., Chi Y., Yin J., Tang X., et al. Phylogenetic analysis of the major causative agents of hand, foot and mouth disease in Suzhou city, Jiangsu province, China, in 2012-2013. Emerg Microb Infect 2015, 4:e12.
35. Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001, 20:895-904.
36. Tung W.S., Bakar S.A., Sekawi Z., Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 2007, 5:6.
37. Liu J.N., Wang W., Duo J.Y., Hao Y., Ma C.M., Li W.B., et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 2010, 28:7444-7451.
38. Foo D.G., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 2007, 125:61-68.
39. Krause A., Joh J.H., Hackett N.R., Roelvink P.W., Bruder J.T., Wickham T.J., et al. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol 2006, 80:5523-5530.
40. Matthews Q.L., Yang P., Wu Q., Belousova N., Rivera A.A., Stoff-Khalili M.A., et al. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J 2008, 5:98.
41. Shao J.J., Wong C.K., Lin T., Lee S.K., Cong G.Z., Sin F.W.Y., et al. Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine. Clin Vaccine Immunol 2010, 18:143-149.
42. Zhou D., Wu T.-L., Emmer K.L., Kurupati R., Tuyishime S., Li Y., et al. Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus. Mol Ther 2012, 21:696-706.
43. Shiratsuchi T., Rai U., Krause A., Worgall S., Tsuji M. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 2010, 120:3688-3701.
44. Pichla-Gollon S.L., Drinker M., Zhou X., Xue F., Rux J.J., et al. Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol 2007, 81:1680-1689.